youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
INCY:NASDAQ
Incyte Corp
$115.71
arrow_downward
-1.04%(-1.22) 1D
$115.00
arrow_downward
-0.61% (-0.71)bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INCY...
Open
$116.75
High
$116.86
Low
$115.12
Mkt. cap
23.45B
Avg. vol.
1.72M
Volume
1.48M
P/E ratio
14.74
52-wk high
$132.58
52-wk low
$84.02
EPS
$7.85
Beta
0.74
Shares outstanding
202.70M
No. of employees
3K
Open
$116.75
High
$116.86
Low
$115.12
Mkt. cap
23.45B
Avg. vol.
1.72M
Volume
1.48M
P/E ratio
14.74
52-wk high
$132.58
52-wk low
$84.02
EPS
$7.85
Beta
0.74
Shares outstanding
202.70M
No. of employees
3K
News stories
From web sources and news partners
Seeking Alpha
·
1 hour ago
Genmab, Incyte team up to develop experimental colorectal cancer treatment (INCY:NASDAQ)
News Corp
·
1 day ago
Incyte Corp. stock outperforms competitors despite losses on the day
Zacks
·
2 days ago
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Yahoo Finance
·
2 days ago
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEO-
Employees2.84K
Founded2002
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websiteincyte.com